Health Canada approves Zyclara Cream for multiple actinic keratoses

Health Canada has approved Zyclara™ (imiquimod) Cream 3.75%, a topical prescription treatment for multiple actinic keratoses (AK) located on the face or balding scalp in adults. Actinic Keratosis is a common skin condition that can lead to squamous cell carcinoma, a form of non-melanoma skin cancer, if left untreated.

“With a shortened course of therapy compared with other prescription creams, Zyclara offers a more simplified treatment regimen which encourages patient compliance”

Actinic keratosis is a precancerous skin condition which can be caused by chronic sun exposure. AK can affect Canadians all year round, and can even manifest in the winter months.

Zyclara Cream is an immune response modifier. This means it works by stimulating the body’s own immune system to recognize and respond to clear AK lesions safely and effectively.

“Zyclara is a safe and effective new option that has many benefits over and above existing treatments,“ said Jefferson J. Gregory, Chairman and CEO of Graceway Pharmaceuticals, LLC. “Zyclara targets visible lesions but also clears sub-clinical lesions that exist beneath the surface of the skin, it’s easy to use and can be applied at home, and unlike other treatment options, it can be used on a large surface area.”

In two double-blind, randomized, placebo-controlled clinical studies, 319 subjects with AK lesions were treated with Zyclara Cream, or a matching placebo cream once daily for two, two-week cycles with a two-week non-treatment period in between. The study found that 35.6 per cent of patients treated with Zyclara Cream had a complete clearance of all lesions compared to only 6.3 per cent in the placebo group. The majority of patients treated with Zyclara Cream experienced a lesion reduction of 81.8 per cent.

Studies also showed Zyclara Cream can be used on a large surface area and not only targets visible lesions, but also clears lesions that are not yet visible but exist beneath the surface of the skin.

“With a shortened course of therapy compared with other prescription creams, Zyclara offers a more simplified treatment regimen which encourages patient compliance,” said Mr. Gregory. “And as a non-invasive therapy, it offers patients a comfortable treatment experience, while still addressing both cosmetic and medical concerns.”

Zylcara Cream is applied by the patient at home in a short course of therapy. It is used once daily, applied at bedtime to the skin of the affected area. Treatment duration is two weeks on, two weeks off, two weeks on, unless otherwise directed by a physician.

In clinical trials, Zyclara Cream was generally well tolerated. The majority of local skin reactions were mild to moderate. The most common side effects included headache, application site pruritus (itching) and irritation, fatigue and nausea.

In addition to imiquimod cream (3.75% and 5%), other treatment options include cryotherapy (freezing), excisional surgery, curettage (scraping), electrodessication (drying), lasers (burning), and topical chemotherapy.

Zyclara Cream is available only by prescription.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Stanford study finds low risk of secondary blood cancers after CAR-T cell therapy